- Zacks•12 days ago
Kite Pharma (KITE) announced that it has entered into a strategic partnership with Daiichi Sankyo to develop and commercialize axicabtagene ciloleucel (KTE-C19) in Japan.
- Moody's•3 months agoAstellas Pharma Inc. -- Moody's: Japanese pharmaceutical companies' expiring drugs patents could prompt strategic alliances
Tokyo, October 20, 2016-- Moody's Japan K.K. says that the expiry of key drug patents over the next 1-3 years will pressure the revenues of the rated Japanese pharmaceutical companies, and could prompt ...
- Zacks•6 months ago
Amgen (AMGN) inked an exclusive agreement with Daiichi Sankyo for the commercialization of nine biosimilars in Japan.
DSNKY : Summary for DAIICHI SANKYO COM SPON ADR EA - Yahoo Finance
Daiichi Sankyo Company, Limited (DSNKY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||21.53 - 22.00|
|52 Week Range||20.02 - 24.69|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||27.65|
|Dividend & Yield||0.61 (2.83%)|
|1y Target Est||N/A|